Literature DB >> 11331052

Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.

M G Shlipak1, W S Browner, H Noguchi, B Massie, C D Frances, M McClellan.   

Abstract

PURPOSE: Angiotensin converting-enzyme (ACE) inhibitors decrease mortality after myocardial infarction among patients with depressed left ventricular function. Beta blockers may also improve survival in these patients. We compared the relative effects of these agents on the survival of elderly patients with a left ventricular ejection fraction less than 40% after myocardial infarction. SUBJECTS AND METHODS: The Cooperative Cardiovascular Project collected data on patients aged 65 years and older who were admitted with myocardial infarction from April 1994 to July 1995, including 20,902 with a measured left ventricular ejection fraction less than 40% before discharge. Using proportional hazard regression models that adjusted for patient characteristics and in-hospital treatments, we compared survival among patients discharged on ACE inhibitors, beta blockers, both medications, or neither medication.
RESULTS: Among patients surviving hospitalization with reduced left ventricular function, 9,108 (44%) were discharged on ACE inhibitors, 2,613 (13%) on beta blockers, 3,309 (16%) on both medications, and 5,872 (28%) on neither medication. Patients treated with ACE inhibitors were more likely to have a prior diagnosis of heart failure and less likely to have undergone revascularization, whereas those treated with beta blockers were more often treated with thrombolytic therapy and aspirin. Patients treated with ACE inhibitors [hazard ratio (HR = 0.80), 0.80; 95% confidence interval (CI), 0.73 to 0.87] or beta blockers (HR = 0.76, 0.76; 95% CI, 0.64 to 0.90) had lower adjusted 1-year mortality than those who were not treated with either medication. The combination of both medications was associated with additional benefit (HR = 0.68, 0.68; 95% CI, 0.59 to 0.80). The relative benefit of each medication was greatest among patients with an ejection fraction less than 30%, a serum creatinine level 2.0 mg/dL or greater, or both. To prevent a death within a year, the number of patients who needed to be treated with both medications varied from 5 to 15, depending on ejection fraction and renal function.
CONCLUSION: ACE inhibitors and beta blockers were associated with similar improvements in survival among elderly patients with reduced left ventricular ejection fraction after myocardial infarction. Our results suggest that patients who can tolerate both medications gain additional benefit from the combination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331052     DOI: 10.1016/s0002-9343(01)00652-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

Review 1.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

Review 2.  The contribution of observational studies to the knowledge of drug effectiveness in heart failure.

Authors:  Daniela Dobre; Dirk J van Veldhuisen; Mike J L DeJongste; Eric van Sonderen; Olaf H Klungel; Robbert Sanderman; Adelita V Ranchor; Flora M Haaijer-Ruskamp
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 3.  Prevention of cardiovascular events in elderly people.

Authors:  Wafik Farah Andrawes; Caroline Bussy; Joël Belmin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Heart failure in subjects with chronic kidney disease: Best management practices.

Authors:  Farhan Aslam; Attiya Haque; Javeria Haque; Jacob Joseph
Journal:  World J Cardiol       Date:  2010-05-26

Review 5.  Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Shoshana Steinbruch; Y Wollman; Doron Schwartz
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

6.  Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.

Authors:  Pupalan Iyngkaran; Merlin Thomas; William Majoni; Nagesh S Anavekar; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2012-10-31       Impact factor: 2.041

Review 7.  Pharmacologic management of the cardiorenal syndrome in heart failure.

Authors:  Henry Krum; Pupalan Iyngkaran; Suree Lekawanvijit
Journal:  Curr Heart Fail Rep       Date:  2009-06

8.  Therapies for acute heart failure in patients with reduced kidney function: a community-based perspective.

Authors:  Robert J Goldberg; Rovshan M Ismailov; Vishnu Patlolla; Darleen Lessard; Frederick A Spencer
Journal:  Am J Kidney Dis       Date:  2008-02-07       Impact factor: 8.860

9.  Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial.

Authors:  Alain Cohen-Solal; Dipak Kotecha; Dirk J van Veldhuisen; Daphne Babalis; Michael Böhm; Andrew J Coats; Michael Roughton; Philip Poole-Wilson; Luigi Tavazzi; Marcus Flather
Journal:  Eur J Heart Fail       Date:  2009-08-01       Impact factor: 15.534

10.  Should beta blockers be used in the treatment of hypertension in the elderly?

Authors:  L Michael Prisant
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.